Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Sana Biotechnology Inc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $78.84, while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| ROBO | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $5.92 |
52-Week Low | $63.04 | $2.68 |
Market Cap | — | $947.48M |
Enterprise Value | — | $860.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $79.65, down 1.14% with a bearish technical signal. The robotics ETF faces mixed momentum as moving averages indicate selling pressure while oscillators remain neutral. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with NVIDIA's AI growth outlook providing sector tailwinds.
The ETF offers diversified exposure to robotics growth themes, though valuation metrics are unavailable. Key risks include sector concentration and AI adoption pace variability. Analyst sentiment appears cautiously optimistic given the structural growth drivers in industrial automation and physical AI applications.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
